SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (10204)9/9/2009 2:16:41 PM
From: IRWIN JAMES FRANKEL2 Recommendations  Read Replies (2) | Respond to of 10345
 
>>And the number of AERs prevented by using Tysabri instead of copaxone or interferons FAR outweighs the risks for patients with active MS (in my opinion.)

I think Harold makes a couple of good points. 1 in 1,200 may overstate the risk. That formulation of the risk totally ignores the risk of untreated or inadequately treated MS.

While my wife was on Copaxone, she had two very bad exacerbations. They were scary - I will spare you the details. She was hospitalized and bed ridden.

She has now been on Tysabri for about 21 months. So far not one exacerbation that we can identify and she has recovered many of her deficits - but not all.

I am grateful for the many years that Copaxone helped slow her disease course - and I do believe that happened.

But Tysabri is indeed a significant advance even with the PML risk counted.

I do hope that ACOR will get Fampridine-SR approved. I think they will. In fact, my wife's doctor must too - since she is about to start my wife on the drug through a compounding pharmacy.

ij



To: Harold Engstrom who wrote (10204)9/9/2009 5:28:57 PM
From: DewDiligence_on_SI  Respond to of 10345
 
>Dew Diligence, my point was that risk clearly does NOT increase with time on drug.<

Are you seriously arguing that the cumulative risk does not increase with time on drug? That’s so preposterous that I won’t bother to respond any further. Regards, Dew



To: Harold Engstrom who wrote (10204)10/21/2009 4:32:15 AM
From: DewDiligence_on_SI  Respond to of 10345
 
>Dew Diligence, my point was that risk clearly does NOT increase with time on drug.<

As noted previously, the above contention is utterly preposterous. Even BIIB now acknowledges that cumulative PML risk increases with time.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News